Healthy Q2 and H1; resulting in consecutive guidance upgrade
04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."
Pages
58
Language
English
Published on
04/08/22
You may also be interested by these reports :
16/03/26
Amplifon has announced the acquisition of GN Store Nord’s hearing business, marking a shift towards a backward integration strategy, which deviates ...
13/03/26
In addition to a downward revision to our estimates, we have also incorporated a 30% discount to peer-based valuation metrics to account for business ...
12/03/26
We have revised our 2025 figures downward as actuals came in weaker than expected, starting with a 3.5% miss on the top line. We were overly ...
05/03/26
Elekta’s Q3 profitability exceeded consensus expectations. Organic sales growth was recorded in EMEA and APAC, while the Americas exhibited weakness. ...